Track topics on Twitter Track topics that are important to you
BioCryst Pharmaceuticals announced the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353 given as a single oral dose for the acute treatment of angioedema attacks in patients with hereditary angioedema (HAE). “We are excited to launch the ZENITH-1 exploratory phase II […]
The post BioCryst to evaluate BCX7353 for hereditary angioedema attacks appeared first on CenterWatch News Online.
Original Article: BioCryst to evaluate BCX7353 for hereditary angioedema attacksNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...